Sales Account Executive (Kansas City)
ArteraFull Time
Mid-level (3 to 4 years), Senior (5 to 8 years)
Candidates should possess a Bachelor’s degree in a related field, along with at least 5 years of experience in sales, preferably within the healthcare or pharmaceutical industry. Strong knowledge of oncology, hematology, chemotherapeutics, and targeted agents is required, as well as the ability to provide an integrated MolDx/SaaS solution utilizing Tempus’ sequencing technology. Excellent negotiation and customer service skills, combined with proficiency in Microsoft Office products, particularly Excel and PowerPoint, are essential. The ability to work independently, manage multiple projects, prioritize tasks, and maintain confidentiality is also necessary.
The Clinical Account Executive will drive strategic business expansion and collaboration opportunities with major U.S. cancer centers, oncology practices, Key Opinion Leaders, and Academic Medical Centers within the assigned territory. They will structure strategic plans for gaining and retaining clients, maximize client-bill contracting opportunities, implement laboratory services agreements, collaborate with sales teams, identify and develop partnering opportunities, promote compliance with new tools, analyze the competitive landscape, develop a comprehensive business plan, and work effectively with multiple departments. The role also involves monitoring performance, developing sales strategies, and demonstrating Tempus’ values through integrity, respect, and trust, with frequent travel exceeding 50%.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.